Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon
16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy)
at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment
with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors
(ACEIs) or angiotensin II type I receptor blockers (ARBs).
Phase:
Phase 3
Details
Lead Sponsor:
Calliditas Therapeutics AB
Treatments:
Antibodies Budesonide Immunoglobulin A Immunoglobulins